Online inquiry

IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ1723MR)

This product GTTS-WQ1723MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_001250.6
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	958
UniProt ID	P25942

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1723MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ9926MR	IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	KB-004
GTTS-WQ8374MR	IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	aTROP2S7
GTTS-WQ14332MR	IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	RG7414
GTTS-WQ4319MR	IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BIVV009
GTTS-WQ8244MR	IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	HLX10
GTTS-WQ7214MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ14493MR	IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	RYI-018
GTTS-WQ15803MR	IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	XmAb14045

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST